skip to main content
Close Icon We use cookies to improve your website experience.  To learn about our use of cookies and how you can manage your cookie settings, please see our Cookie Policy.  By continuing to use the website, you consent to our use of cookies.
Global Search Configuration

Refine Results

Clear All

Specialism

Show More

Resources

Show More

Show More

Products

Show More

Show More

21 Total results for product and free and sample content found

Generics Bulletin

Lupin Offloads Kyowa For $525m But Not Exiting Japan

By Vibha Ravi 13 Nov 2019

Analysis

Lupin plans to invest in acquisitions and organic growth in the US and India after selling Japanese subsidiary Kyowa Pharma for an enterprise value of around $525m to Japan private equity group Unison Capital. But the Indian firm stresses it is not exiting Japan and will continue to look for marketing partnerships.

Topic Deal trends Strategy

In Vivo

How Proximity Creates Partnerships

By William Looney 08 Nov 2019

Article

Former Amgen R&D lead Sean Harper talks exclusively to In Vivo about his new role as a venture capitalist, joining veteran industry investor Beth Seidenberg as co-founder of Los Angeles-based Westlake Village BioPartners.

Topic Business strategies Deal trends

Scrip

Gene Therapy 'Vant' Unveiled As Dainippon, Roivant Finalise $3bn Deal

By Ian Haydock 06 Nov 2019

Article

Japanese firm signs definitive agreement to acquire Roivant's interests in five 'vants' initially, including new gene therapy operation, as ex-Genentech president named head of new entity.

Topic Business strategies Deal trends

Scrip

Ready, Set, Lowest: Who Won China's Latest Drug Bidding War?

By Brian Yang 18 Oct 2019

Ready, Set, Lowest: Who Won China's Latest Drug Bidding War?

Multinationals are feeling the heat to win in China's latest drug procurement battle. The winning prices have surprised even previous winners and may have a profound and long-lasting impact on the pharma sector.

Topic Deal trends Strategy

Awareness

MS Outlook 2020 Scrip 100

24 Jul 2019

Outlook 2020 is the annual look at the performance and future prospects of the global pharmaceutical industry. This year, the supplement will reach more people than ever before with distribution to In Vivo, Pink Sheet, Scrip, Medtech Insight and Generics bulletin subscribers PLUS events such as Biotech Showcase and Partnerships in Clinical Trials.

Topic Deal trends BioPharmaceutical Business strategies

Pink Sheet

The Drug Pricing Article Pack

15 Jul 2019

Get expert insights into the events driving drug pricing polices around the world.  This Article Pack covers drug pricing issues for: The EU - Vital developments for Norway, Denmark, and other EU countries, including the UK The US – Essential drug pricing info from a country where the issue has taken center stage Australia – Developments surrounding drug pricing issues in Australia

Topic Deal trends Policy and regulation

Datamonitor Healthcare

Top 10 Best Selling Drugs of 2018 Fund US and EU Pharma RD

15 Jul 2019

Our latest whitepaper lists the top selling drugs last year, who developed them and the strategies behind their success. We drew from three of our top products to create our most recent whitepaper, Datamonitor Health Care, Biomedtracker and Pharmaprojects. You can experience them all for yourself. 

Topic Drug review Strategy Deal trends

Pink Sheet

Lessons From Mercosur Multi-Country Pricing Negotiations

By Francesca Bruce 05 Jul 2019

Lessons From Mercosur Multi-Country Pricing Negotiations

Latin American joint price negotiations have proved successful and other countries are taking note.

Topic Business strategies Deal trends

Scrip

Under The Radar Potential Small Cap Takeover Targets

By Joseph Haas 03 Jul 2019

Under The Radar Potential Small Cap Takeover Targets

Looking back at the second quarter, PharmaVitae analysts have selected 10 biopharma companies with market caps under $3bn they think are primed for acquisition – and the likely candidates for a buy-out.

Topic Business strategies BioPharmaceutical Deal trends

Next steps

Getting a demo tailored to your needs is the best way to see how our solutions will help you gain an advantage.

Request live demo now:

Our team is always happy to hear from you. Please call us at:

  • US Toll-Free  : +1 888 670 8900
  • US Toll           : +1 908 547 2200
  • UK & Europe : +44 (20) 337 73737
  • Australia        : +61 2 8705 6907
  • Japan              : +81 3 6273 4260

Or please submit your inquiry via the form so that we can provide you the best possible customer service.

Have an immediate and specific information need?

Browse and buy from 1000s of analysis and research reports now: